Literature DB >> 25023054

Comparison of the clinicopathological characteristics and the survival outcomes between the Siewert type II/III adenocarcinomas.

Wei-Han Zhang1, Xin-Zu Chen, Kai Liu, Kumar Anil, Kun Yang, Jia-Ping Chen, Zong-Guang Zhou, Jian-Kun Hu.   

Abstract

The aim of the study was to analyze the clinicopathological characteristics and survival outcomes in Siewert type II and Siewert type III tumors. The clinicopathological characteristics and survival outcomes were analyzed in patients diagnosed with Siewert II/III tumors, who underwent transabdominal gastrectomy from Jan 2006 to Dec 2010. A total of 321 patients diagnosed with Siewert II/III tumors who underwent gastrectomy were enrolled in this study. Siewert III tumors are larger and have a higher proportion of Borrmann 3-4 types than Siewert II tumors (p < 0.05). For Siewert II and the Siewert III tumors, the 3-year overall survival rate was 59.1 versus 57.1 %, respectively, and the median survival time was 46.0 (31.5-60.5) months versus 46.0 (31.3-60.7) months, respectively. Positive proximal resection margin, large tumor size, Borrmann 3-4 types, poor or undifferentiated degree and advanced T stages and N stages were found to be poor prognostic risk factors for the overall survival outcomes by univariate analysis. Multivariate analysis revealed that the differentiation degree (poor and undifferentiated) and advanced T and N stages were independent prognostic factors for poor overall survival. Siewert III tumors were larger and had a lower differentiation degree than Siewert II tumors, whereas there was no difference in the survival outcomes.

Entities:  

Mesh:

Year:  2014        PMID: 25023054     DOI: 10.1007/s12032-014-0116-3

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  33 in total

1.  Should adenocarcinoma of the esophagogastric junction be classified as esophageal cancer? A comparative analysis according to the seventh AJCC TNM classification.

Authors:  Yun-Suhk Suh; Dong-Seok Han; Seong-Ho Kong; Hyuk-Joon Lee; Young Tae Kim; Woo-Ho Kim; Kuhn Uk Lee; Han-Kwang Yang
Journal:  Ann Surg       Date:  2012-05       Impact factor: 12.969

2.  Outcomes of Abdominal Total Gastrectomy for Type II and III Gastroesophageal Junction Tumors: Single Center's Experience in Korea.

Authors:  Kyoung Tai Kim; Oh Jeong; Mi Ran Jung; Seong Yeop Ryu; Young-Kyu Park
Journal:  J Gastric Cancer       Date:  2012-03-30       Impact factor: 3.720

3.  The pattern of metastatic lymph node dissemination from adenocarcinoma of the esophagogastric junction.

Authors:  S M Dresner; P J Lamb; M K Bennett; N Hayes; S M Griffin
Journal:  Surgery       Date:  2001-01       Impact factor: 3.982

4.  Global cancer statistics, 2002.

Authors:  D Max Parkin; Freddie Bray; J Ferlay; Paola Pisani
Journal:  CA Cancer J Clin       Date:  2005 Mar-Apr       Impact factor: 508.702

5.  Early carcinoma of the gastric cardia in Japan: is it different from that in the West?

Authors:  T Okabayashi; T Gotoda; H Kondo; T Inui; H Ono; D Saito; S Yoshida; M Sasako; T Shimoda
Journal:  Cancer       Date:  2000-12-15       Impact factor: 6.860

6.  Cardia carcinoma considered as a distinct clinical entity.

Authors:  B Husemann
Journal:  Br J Surg       Date:  1989-02       Impact factor: 6.939

Review 7.  Surgical management of esophagogastric junction tumors.

Authors:  Burkhard H A von Rahden; Hubert J Stein; J Rüdiger Siewert
Journal:  World J Gastroenterol       Date:  2006-11-07       Impact factor: 5.742

8.  A prospective comparison of transthoracic and transhiatal resection for esophageal carcinoma in Asians.

Authors:  Shah-Hwa Chou; Hung-Yi Chuang; Meei-Feng Huang; Chia-Hua Lee; Harvey Man-Pun Yau
Journal:  Hepatogastroenterology       Date:  2009 May-Jun

9.  Transthoracic resection versus non-transthoracic resection for gastroesophageal junction cancer: a meta-analysis.

Authors:  Kun Yang; Hai-Ning Chen; Xin-Zu Chen; Qing-Chun Lu; Lin Pan; Jie Liu; Bin Dai; Bo Zhang; Zhi-Xin Chen; Jia-Ping Chen; Jian-Kun Hu
Journal:  PLoS One       Date:  2012-06-04       Impact factor: 3.240

10.  The impact of operative approach on outcome of surgery for gastro-oesophageal tumours.

Authors:  Stuart A Suttie; Alan Gk Li; Martha Quinn; Kenneth Gm Park
Journal:  World J Surg Oncol       Date:  2007-08-20       Impact factor: 2.754

View more
  4 in total

1.  Comparison of survival outcomes between transthoracic and transabdominal surgical approaches in patients with Siewert-II/III esophagogastric junction adenocarcinoma: a single-institution retrospective cohort study.

Authors:  Weihan Zhang; Xinzu Chen; Kai Liu; Kun Yang; Xiaolong Chen; Ying Zhao; Yongfan Zhao; Jiaping Chen; Longqi Chen; Jiankun Hu
Journal:  Chin J Cancer Res       Date:  2016-08       Impact factor: 5.087

2.  Identification of Sensitivity Predictors of Neoadjuvant Chemotherapy for the Treatment of Adenocarcinoma of Gastroesophageal Junction.

Authors:  Shoumiao Li; Baozhong Li; Jiaxiang Wang; Da Zhang; Zhiqiang Liu; Zhizhong Zhang; Wei Zhang; Yunjie Wang; Dongxiao Bai; Jianyun Guan; Yong Zhang
Journal:  Oncol Res       Date:  2017-01-02       Impact factor: 5.574

3.  Survival Benefit of Pyloric Lymph Node Dissection for Siewert Type II/III Adenocarcinoma of the Esophagogastric Junction Based on Tumor Diameter: A Large Cohort Study.

Authors:  Xia Lin; Zhengyan Li; Chenjun Tan; Xiaoshuang Ye; Jie Xiong; Jiajia Liu; Ao Mo; Yan Shi; Feng Qian; Peiwu Yu; Yongliang Zhao
Journal:  Front Oncol       Date:  2021-12-01       Impact factor: 6.244

4.  Priority of lymph node dissection for advanced esophagogastric junction adenocarcinoma with the tumor center located below the esophagogastric junction.

Authors:  Ming-Zhi Cai; Chen-Bin Lv; Li-Sheng Cai; Qiu-Xian Chen
Journal:  Medicine (Baltimore)       Date:  2019-12       Impact factor: 1.889

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.